Predicting Response to Incretin Based Agents in Type 2 Diabetes (PRIBA)
Does Urinary C-peptide Creatinine Ratio Predict Response to Incretin Based Agents in Type 2 Diabetes
Sponsor: National Institute for Health Research, United Kingdom
A observational or N/A phase clinical study on Type2 Diabetes, this trial is completed. The trial is conducted by National Institute for Health Research, United Kingdom and has accumulated 11 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Nov 2020 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Aug 2017 [monthly]
Completed NA
First recorded
May 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute for Health Research, United Kingdom
- Royal Devon and Exeter NHS Foundation Trust
- University of Exeter
For direct contact, visit the study record on ClinicalTrials.gov .